Headquartered in Fremont, CA Fiscal year ends December NASDAQ: PSNL personalis.com
Personalis, Inc. is a genomics company focused on precision oncology, specializing in advanced personalized cancer testing. Its core product, NeXT Personal, is a tumor-informed minimal residual disease (MRD) assay designed to detect traces of cancer at ultrasensitive levels, guide treatment decisions, and monitor recurrence throughout the patient journey. The company combines tumor-and-normal profiling with proprietary algorithms to deliver genomic insights even as cancer evolves. Personalis serves two primary markets: clinical diagnostics, where it provides MRD testing to oncologists for cancer recurrence monitoring (now Medicare-covered for lung cancer, immunotherapy monitoring, neoadjuvant breast cancer, and other indications), and pharma testing services, where it supports biopharma companies in clinical trials and biomarker strategy for drug development. The company also provides population-scale genomic sequencing services, notably through the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP). On July 20, 2026, Personalis entered into a definitive merger agreement with Tempus AI, Inc., which if completed would combine the two companies' complementary capabilities in genomics and precision medicine. Updated
Tempus AI wrote a $1.5 billion check for a genomics company most investors had never heard of, and one blockbuster clinical trial announcement just changed everything about how that deal looks.
Personalis, Inc. is a genomics company focused on precision oncology, specializing in advanced personalized cancer testing.
The Wall Street consensus 12-month price target for PSNL is $15.17.
